87 related articles for article (PubMed ID: 6312589)
1. [Phase I study of alizapride in cancer patients treated with cisplatin].
Nicaise C; Rozencweig M; Ortmans M; Frisque C; Bleiberg H
Sem Hop; 1983 Sep; 59(31):2161-5. PubMed ID: 6312589
[TBL] [Abstract][Full Text] [Related]
2. [Evaluation of a new antiemetic, alizapride, in cancerology (author's transl)].
Cupissol D; Favier F; Favier C; Serrou B
Sem Hop; 1982 Jun; 58(22):1370-3. PubMed ID: 6287597
[TBL] [Abstract][Full Text] [Related]
3. [Control of the emesis induced by cisplatin in patients with head and neck neoplasms. Randomized study of metoclopramide alizapride and placebo].
Denaro A; Rossi M; Garozzo A; Matera M; Neri V
G Ital Oncol; 1990; 10(1-2):29-34. PubMed ID: 2192985
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the antiemetic efficacy of two high-dose benzamides, metoclopramide and alizapride, against cisplatin-induced emesis.
Saller R; Hellenbrecht D
Cancer Treat Rep; 1985 Nov; 69(11):1301-3. PubMed ID: 3912040
[TBL] [Abstract][Full Text] [Related]
5. [Alizapride in a double-blind trial with metoclopramide in nausea and vomiting caused by radiotherapy].
Budach V; Krüger K
Fortschr Med; 1983 Oct; 101(39):1792-4. PubMed ID: 6642386
[TBL] [Abstract][Full Text] [Related]
6. The antiemetic activity of high-dose alizapride and high-dose metoclopramide in patients receiving cancer chemotherapy: a prospective, randomized, double-blind trial.
Joss RA; Galeazzi RL; Bischoff AK; Pirovino M; Ryssel HJ; Brunner KW
Clin Pharmacol Ther; 1986 Jun; 39(6):619-24. PubMed ID: 3519041
[TBL] [Abstract][Full Text] [Related]
7. Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience.
Sorbe BG
Semin Oncol; 1994 Oct; 21(5 Suppl 9):20-6. PubMed ID: 9113123
[TBL] [Abstract][Full Text] [Related]
8. A prospective randomized double-blind crossover study comparing the antiemetic activity of alizapride and metoclopramide in patients receiving cisplatin chemotherapy.
Basurto C; Roila F; Del Favero A; Ballatori E; Minotti V; Tonato M
Cancer Invest; 1988; 6(5):475-9. PubMed ID: 3063335
[TBL] [Abstract][Full Text] [Related]
9. Alizapride alone or alizapride-dexamethasone compared with metoclopramide-dexamethasone in patients at high risk of acute emesis after cisplatin. A randomized cross-over study.
Pollera CF; Nardi M; Marolla P; Calabresi F
Acta Oncol; 1991; 30(6):725-9. PubMed ID: 1958393
[TBL] [Abstract][Full Text] [Related]
10. [Antiemetic effects of MS-5080 associated with cisplatin chemotherapy--an attempt in assessment based on the sample score system using multivariate analysis].
Niijima T; Aso Y; Akaza H; Isurugi K; Kondo Y; Fujita K; Fukutani K; Ishii Y; Kawabe K; Kinoshita K
Gan To Kagaku Ryoho; 1987 Dec; 14(12):3319-27. PubMed ID: 3688894
[TBL] [Abstract][Full Text] [Related]
11. Alizapride, a new substituted benzamide, as an antiemetic during cancer chemotherapy.
Joss RA; Galeazzi RL; Bischoff AK; Brunner KW
Eur J Clin Pharmacol; 1985; 27(6):721-5. PubMed ID: 3987777
[TBL] [Abstract][Full Text] [Related]
12. Anti-emetic effect of high-dose metoclopramide vs alizapride--a randomised crossover study.
Seng KT; Tiong CE; Hiang TC
Br J Clin Pharmacol; 1994 Sep; 38(3):282-4. PubMed ID: 7826833
[TBL] [Abstract][Full Text] [Related]
13. [Clinical efficacy of GG032X tablets, a new dosage form of ondansetron (fast dispersing tablet), on cisplatin-induced nausea and emesis].
Ariyoshi Y; Nukariya N; Akasaka Y; Suminaga M; Ota J; Ikeda M; Taguchi T
Gan To Kagaku Ryoho; 1997 Jun; 24(8):995-1011. PubMed ID: 9212810
[TBL] [Abstract][Full Text] [Related]
14. [Antiemetic and antinauseant effect of alizapride in patients subjected to antiblastic infusion chemotherapy in a day-hospital regime].
Cicchetti F; Viganò P; Borghi CM; Franzini A; Alfano G; Antolini C
G Ital Oncol; 1989; 9(1):18-21. PubMed ID: 2707835
[TBL] [Abstract][Full Text] [Related]
15. Activity of a new antiemetic agent: alizapride. A randomized double-blind crossover controlled trial.
Bleiberg H; Gerard B; Dalesio O; Crespeigne N; Rozencweig M
Cancer Chemother Pharmacol; 1988; 22(4):316-20. PubMed ID: 3048762
[TBL] [Abstract][Full Text] [Related]
16. [Randomized comparative trial of a new anti-emetic: nabilone, in cancer patients treated with cisplatin].
George M; Pejovic MH; Thuaire M; Kramar A; Wolff JP
Biomed Pharmacother; 1983; 37(1):24-7. PubMed ID: 6311306
[TBL] [Abstract][Full Text] [Related]
17. A report comparing the use of tropisetron (Navoban), a 5-HT3 antagonist, with a standard antiemetic regimen of dexamethasone and metoclopramide in cisplatin-treated patients under conditions of severe emesis.
Madej G; Krzakowski M; Pawinski A; Lasota W; Rogowski W; Skoneczna I
Semin Oncol; 1994 Oct; 21(5 Suppl 9):3-6. PubMed ID: 9113119
[TBL] [Abstract][Full Text] [Related]
18. Double-blind crossover trial of droperidol, metoclopramide, and prochlorperazine as antiemetics in cisplatin therapy.
Lewis GO; Bernath AM; Ellison NM; Gallagher JG; Porter PA; Rine KT
Clin Pharm; 1984; 3(6):618-21. PubMed ID: 6391784
[TBL] [Abstract][Full Text] [Related]
19. High-dose alizapride versus high-dose domperidone: a double-blind comparative study in the management of cis-platinum-induced emesis.
Huys J; Troch M; Bourguignon RP; Smets P
Curr Med Res Opin; 1985; 9(6):400-6. PubMed ID: 3886305
[TBL] [Abstract][Full Text] [Related]
20. [Randomized study of the antiemetic efficacy of alizapride versus alizapride + dexamethasone].
Epifani C; Scognamiglio G; Prete C; Alberio F; Gini G; Valli M
G Ital Oncol; 1990; 10(4):115-9. PubMed ID: 2093079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
